{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:35:18Z","timestamp":1793932518301,"version":"4.8.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006310","name":"Swedish Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Erling-Persson Foundation"},{"DOI":"10.13039\/501100004885","name":"Ume\u00e5 University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004885","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002960","name":"V\u00e4sterbotten County Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"crossref"}]},{"name":"King Gustaf V and Queen Victoria Freemason Foundation"},{"name":"Swedish Parkinson Foundation"},{"DOI":"10.13039\/100016756","name":"Kempe Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish PD Association"},{"name":"European Research Council"},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["#2018-02532"],"award-info":[{"award-number":["#2018-02532"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["#681712"],"award-info":[{"award-number":["#681712"]}]},{"name":"Swedish State Support for Clinical Research","award":["#ALFGBG-720931"],"award-info":[{"award-number":["#ALFGBG-720931"]}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["#201809-2016862"],"award-info":[{"award-number":["#201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["#ADSF-21-831376-C"],"award-info":[{"award-number":["#ADSF-21-831376-C"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["#ADSF-21-831381-C"],"award-info":[{"award-number":["#ADSF-21-831381-C"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["#ADSF-21-831377-C"],"award-info":[{"award-number":["#ADSF-21-831377-C"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007436","name":"Erling-Persson Family Foundation","doi-asserted-by":"crossref","award":["#FO2019-0228"],"award-info":[{"award-number":["#FO2019-0228"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007436","name":"Erling-Persson Family Foundation","doi-asserted-by":"crossref","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UK Dementia Research Institute at UCL"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The progression of cognitive decline is heterogeneous in the three most common idiopathic parkinsonian diseases: Parkinson disease, multiple system atrophy and progressive supranuclear palsy. The causes for this heterogeneity are not fully understood, and there are no validated biomarkers that can accurately identify patients who will develop dementia and when. In this population-based, prospective study, comprehensive neuropsychological testing was performed repeatedly in new-onset, idiopathic parkinsonism. Dementia was diagnosed until 10 years and participants (N\u2009=\u2009210) were deeply phenotyped by multimodal clinical, biochemical, genetic and brain imaging measures. At baseline, before the start of dopaminergic treatment, mild cognitive impairment was prevalent in 43.4% of the patients with Parkinson disease, 23.1% of the patients with multiple system atrophy and 77.8% of the patients with progressive supranuclear palsy. Longitudinally, all three diseases had a higher incidence of cognitive decline compared with healthy controls, but the types and severity of cognitive dysfunctions differed. In Parkinson disease, psychomotor speed and attention showed signs of improvement after dopaminergic treatment, while no such improvement was seen in other diseases. The 10-year cumulative probability of dementia was 54% in Parkinson disease and 71% in progressive supranuclear palsy, while there were no cases of dementia in multiple system atrophy. An easy-to-use, multivariable model that predicts the risk of dementia in Parkinson disease within 10 years with high accuracy (area under the curve: 0.86, P\u2009&amp;lt;\u20090.001) was developed. The optimized model adds CSF biomarkers to four easily measurable clinical features at baseline (mild cognitive impairment, olfactory function, motor disease severity and age). The model demonstrates a highly variable but predictable risk of dementia in Parkinson disease, e.g. a 9% risk within 10 years in a patient with normal cognition and CSF amyloid-\u03b242 in the highest tertile, compared with an 85% risk in a patient with mild cognitive impairment and CSF amyloid-\u03b242 in the lowest tertile. Only small or no associations with cognitive decline were found for factors that could be easily modifiable (such as thyroid dysfunction). Risk factors for cognitive decline in multiple system atrophy and progressive supranuclear palsy included signs of systemic inflammation and eye movement abnormalities. The predictive model has high accuracy in Parkinson disease and might be used for the selection of patients into clinical trials or as an aid to improve the prevention of dementia.<\/jats:p>","DOI":"10.1093\/braincomms\/fcac040","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T16:25:06Z","timestamp":1647275106000},"source":"Crossref","is-referenced-by-count":39,"title":["Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-2475","authenticated-orcid":false,"given":"David","family":"B\u00e4ckstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Clinical Science, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"Department of Neurology, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gran\u00e5sen","sequence":"additional","affiliation":[{"name":"Epidemiology and Global Health Unit, Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna Jakobson","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Radiation Sciences, Diagnostic Radiology and Ume\u00e5 Center for Functional Brain Imaging, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Riklund","sequence":"additional","affiliation":[{"name":"Department of Radiation Sciences, Diagnostic Radiology and Ume\u00e5 Center for Functional Brain Imaging, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-053X","authenticated-orcid":false,"given":"Miles","family":"Trupp","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"Department of Neurodegenerative Disease and UCL Queen Square Institute of Neurology, London, UK"},{"name":"UK Dementia Research Institute at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Forsgren","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena Eriksson","family":"Domell\u00f6f","sequence":"additional","affiliation":[{"name":"Department of Psychology, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"issue":"Pt 8","key":"2022032516135569100_fcac040-B1","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awq158","article-title":"Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy","volume":"133","author":"Brown","year":"2010","journal-title":"Brain"},{"issue":"4","key":"2022032516135569100_fcac040-B2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"22","key":"2022032516135569100_fcac040-B3","doi-asserted-by":"crossref","first-page":"e2045","DOI":"10.1212\/WNL.0000000000006576","article-title":"Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study","volume":"91","author":"B\u00e4ckstr\u00f6m","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"2022032516135569100_fcac040-B4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/WCO.0b013e3283168df0","article-title":"Dementia in Parkinson\u2019s disease","volume":"21","author":"Aarsland","year":"2008","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"2022032516135569100_fcac040-B5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","article-title":"The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort","volume":"84","author":"Williams-Gray","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2022032516135569100_fcac040-B6","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/01.WNL.0000158422.41380.82","article-title":"Cognitive status correlates with neuropathologic stage in Parkinson disease","volume":"64","author":"Braak","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"2022032516135569100_fcac040-B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol"},{"issue":"6","key":"2022032516135569100_fcac040-B8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/brain\/awv104","article-title":"Parkinson\u2019s disease dementia: A neural networks perspective","volume":"138","author":"Gratwicke","year":"2015","journal-title":"Brain"},{"issue":"6","key":"2022032516135569100_fcac040-B9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ana.24664","article-title":"\u03b1-synuclein genetic variability: A biomarker for dementia in Parkinson disease","volume":"79","author":"Guella","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"2022032516135569100_fcac040-B10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","article-title":"\u03b1-Synuclein strains target distinct brain regions and cell types","volume":"23","author":"Lau","year":"2020","journal-title":"Nat Neurosci"},{"issue":"3","key":"2022032516135569100_fcac040-B11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","article-title":"Parkinson disease with dementia: Comparing patients with and without Alzheimer pathology","volume":"23","author":"Sabbagh","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"2022032516135569100_fcac040-B12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","article-title":"Amyloid-beta (A\u03b2) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with A\u03b2 pathology","volume":"105","author":"Bassil","year":"2020","journal-title":"Neuron"},{"issue":"2","key":"2022032516135569100_fcac040-B13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ane.12375","article-title":"Cognitive function in the early phase of Parkinson\u2019s disease, a five-year follow-up","volume":"132","author":"Domell\u00f6f","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"2022032516135569100_fcac040-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2017.02.017","article-title":"Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson\u2019s disease","volume":"38","author":"Domell\u00f6f","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"2022032516135569100_fcac040-B15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson\u2019s disease","volume":"17","author":"Marinus","year":"2018","journal-title":"Lancet Neurol"},{"issue":"12","key":"2022032516135569100_fcac040-B16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid {beta} 1\u201342 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"issue":"20","key":"2022032516135569100_fcac040-B17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","article-title":"CSF A\u03b242 predicts early-onset dementia in Parkinson disease","volume":"82","author":"Alves","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"2022032516135569100_fcac040-B18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease","volume":"72","author":"B\u00e4ckstr\u00f6m","year":"2015","journal-title":"JAMA Neurol"},{"issue":"8","key":"2022032516135569100_fcac040-B19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(17)30122-9","article-title":"Prediction of cognition in Parkinson\u2019s disease with a clinical-genetic score: A longitudinal analysis of nine cohorts","volume":"16","author":"Liu","year":"2017","journal-title":"Lancet Neurol"},{"key":"2022032516135569100_fcac040-B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41531-020-00121-2","article-title":"Multivariate prediction of dementia in Parkinson\u2019s disease","volume":"6","author":"Phongpreecha","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"key":"2022032516135569100_fcac040-B21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2022032516135569100_fcac040-B22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12916-021-02159-2","article-title":"Non-genetic risk and protective factors and biomarkers for neurological disorders: A meta-umbrella systematic review of umbrella reviews","volume":"19","author":"Mentis","year":"2021","journal-title":"BMC Med"},{"issue":"6","key":"2022032516135569100_fcac040-B23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"2022032516135569100_fcac040-B24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol"},{"issue":"12","key":"2022032516135569100_fcac040-B25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/mds.27198","article-title":"Cognitive impairment in progressive supranuclear palsy is associated with tau burden","volume":"32","author":"Koga","year":"2017","journal-title":"Mov Disord"},{"issue":"3","key":"2022032516135569100_fcac040-B26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/mds.22987","article-title":"Incidence of Parkinson\u2019s disease and parkinsonism in northern Sweden: A population-based study","volume":"25","author":"Linder","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"2022032516135569100_fcac040-B27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2990.1989.tb01147.x","article-title":"The significance of the Lewy body in the diagnosis of idiopathic Parkinson\u2019s disease","volume":"15","author":"Gibb","year":"1989","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"2022032516135569100_fcac040-B28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","article-title":"Consensus statement on the diagnosis of multiple system atrophy","volume":"163","author":"Gilman","year":"1999","journal-title":"J Neurol Sci"},{"issue":"1","key":"2022032516135569100_fcac040-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"issue":"10","key":"2022032516135569100_fcac040-B30","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","article-title":"Variable expression of Parkinson\u2019s disease: A base-line analysis of the DATATOP cohort","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"issue":"3 Pt 1","key":"2022032516135569100_fcac040-B31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005537-199603000-00021","article-title":"Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT)","volume":"106","author":"Doty","year":"1996","journal-title":"Laryngoscope"},{"key":"2022032516135569100_fcac040-B32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"3","key":"2022032516135569100_fcac040-B33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement disorder society task force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"issue":"12","key":"2022032516135569100_fcac040-B34","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"2022032516135569100_fcac040-B35","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"B\u00e4ckstr\u00f6m","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"2022032516135569100_fcac040-B36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jalz.2011.09.230","article-title":"Risk of dementia in an elderly population of Parkinson\u2019s disease patients: A 15-year population-based study","volume":"8","author":"Perez","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2022032516135569100_fcac040-B37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"2022032516135569100_fcac040-B38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2017.96","article-title":"A clinicopathological approach to the diagnosis of dementia","volume":"13","author":"Elahi","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"2022032516135569100_fcac040-B39","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archneur.1988.00520350032011","article-title":"Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson\u2019s disease","volume":"45","author":"Dubois","year":"1988","journal-title":"Arch Neurol"},{"issue":"3","key":"2022032516135569100_fcac040-B40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4103\/0028-3886.27150","article-title":"Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson\u2019s disease","volume":"54","author":"Krishnan","year":"2006","journal-title":"Neurol India"},{"issue":"Suppl 1","key":"2022032516135569100_fcac040-B41","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.parkreldis.2015.09.041","article-title":"The phenotypic spectrum of progressive supranuclear palsy","volume":"22","author":"Respondek","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"2022032516135569100_fcac040-B42","doi-asserted-by":"crossref","first-page":"537360","DOI":"10.3389\/fneur.2020.537360","article-title":"Cognitive profile and its evolution in a cohort of multiple system atrophy patients","volume":"11","author":"Sambati","year":"2020","journal-title":"Front Neurol"},{"issue":"9","key":"2022032516135569100_fcac040-B43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"2022032516135569100_fcac040-B44","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/brain\/awn065","article-title":"Clinical outcomes of progressive supranuclear palsy and multiple system atrophy","volume":"131","author":"O\u2019Sullivan","year":"2008","journal-title":"Brain"},{"issue":"7","key":"2022032516135569100_fcac040-B45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/mds.25880","article-title":"Cognitive impairment in multiple system atrophy: A position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group","volume":"29","author":"Stankovic","year":"2014","journal-title":"Mov Disord"},{"issue":"1","key":"2022032516135569100_fcac040-B46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.157370","article-title":"The role of DAT-SPECT in movement disorders","volume":"81","author":"K\u00e4gi","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2022032516135569100_fcac040-B47","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42: A cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"2022032516135569100_fcac040-B48","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/brain\/awab005","article-title":"Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder","volume":"144","author":"Stefani","year":"2021","journal-title":"Brain"},{"issue":"10","key":"2022032516135569100_fcac040-B49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2022032516135569100_fcac040-B50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/mds.25352","article-title":"Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson\u2019s disease?","volume":"28","author":"Duncan","year":"2013","journal-title":"Mov Disord"},{"key":"2022032516135569100_fcac040-B51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.06.025","article-title":"Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson\u2019s disease","volume":"56","author":"O\u2019Keeffe","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"22","key":"2022032516135569100_fcac040-B52","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.3390\/ijms21228519","article-title":"CSF biomarkers reflecting protein pathology and axonal degeneration are associated with memory, attentional, and executive functioning in early-stage Parkinson\u2019s disease","volume":"21","author":"Oosterveld","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2022032516135569100_fcac040-B53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mds.28342","article-title":"Genome-wide association studies of cognitive and motor progression in Parkinson\u2019s disease","volume":"36","author":"Tan","year":"2021","journal-title":"Mov Disord"},{"issue":"2","key":"2022032516135569100_fcac040-B54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(20)30394-X","article-title":"Genetic determinants of survival in progressive supranuclear palsy: A genome-wide association study","volume":"20","author":"Jabbari","year":"2021","journal-title":"Lancet Neurol"},{"key":"2022032516135569100_fcac040-B55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fneur.2010.00147","article-title":"The disturbance of gaze in progressive supranuclear palsy: Implications for pathogenesis","volume":"1","author":"Chen","year":"2010","journal-title":"Front Neurol"},{"key":"2022032516135569100_fcac040-B56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cortex.2020.12.019","article-title":"Spatial attention and spatial short term memory in PSP and Parkinson\u2019s disease","volume":"137","author":"Smith","year":"2021","journal-title":"Cortex"},{"issue":"22","key":"2022032516135569100_fcac040-B57","doi-asserted-by":"crossref","first-page":"e1989","DOI":"10.1212\/WNL.0000000000005610","article-title":"[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy","volume":"90","author":"Passamonti","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"2022032516135569100_fcac040-B58","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","article-title":"Neuroinflammation predicts disease progression in progressive supranuclear palsy","volume":"92","author":"Malpetti","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2022032516135569100_fcac040-B59","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/ana.25911","article-title":"Neuroinflammation and tau colocalize in vivo in progressive supranuclear palsy","volume":"88","author":"Malpetti","year":"2020","journal-title":"Ann Neurol"},{"issue":"1","key":"2022032516135569100_fcac040-B60","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1038\/s41598-019-44234-y","article-title":"Increased prefrontal cortex interleukin-2 protein levels and shift in the peripheral T cell population in progressive supranuclear palsy patients","volume":"9","author":"Rydbirk","year":"2019","journal-title":"Sci Rep"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcac040\/42956597\/fcac040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/2\/fcac040\/43013086\/fcac040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/2\/fcac040\/43013086\/fcac040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T17:36:01Z","timestamp":1648229761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcac040\/6548788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcac040","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,1]]},"article-number":"fcac040"}}